Ondansetron derivatives as potential PTP1B inhibitors for treating type 2 diabetes mellitus: in silico, in vitro, and in vivo analysis.

Front Pharmacol · 2026 · PMC13272487 · PMID 42318345

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Highly significant p values less than 0.0001 were observed, indicating a prominent difference between the high fat diet + STZ and other treatment groups.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Ondansetron derivatives as potential PTP1B inhibitors for treating type 2 diabetes mellitus: &lt;i&gt;in silico&lt;/i&gt;, &lt;i&gt;in vitro&lt;/i&gt;, and &lt;i&gt;in vivo&lt;/i&gt; analysis.

The sentences

Ondansetron derivatives as potential PTP1B inhibitors for treating type 2 diabetes mellitus: <i>in silico</i>, <i>in vitro</i>, and <i>in vivo</i> analysis.